Overview

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Status:
Completed
Trial end date:
2013-08-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, pharmacokinetics, and preliminary efficacy information of JNJ-40346527 in patients with relapsed or refractory Hodgkin lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC